If your results are too good, NEJM will reject your paper
kirschsubstack.com
Discover more from Steve Kirsch's newsletter
I write about COVID mitigation policies, vaccines, neurological diseases and conditions, corruption, censorship, and early treatments. The data shows that vaccines are ruining the health of Americans and driving the epidemic in neurological conditions.
Over 231,000 subscribers
Continue reading
If your results are too good, NEJM will reject your paper
And if you write about ivermectin, CUREUS will reject your paper.
Flavio Cadegiani sent me this slide:
Here’s a closer shot of the text (click the image to magnify):
Basically,
If your results are too good (as in the clinical trial of proxalutamide for treating COVID), NEJM is required to reject your paper even if they can’t find any other problems.
CUREUS will reject your paper if it is about ivermectin (even if Pierre Kory is a co-author). They don’t like to publish on controversial topics. It is better to wait for the censorship to resolve the dispute rather than allow differing points of view to be surfaced in the scientific literature.
That’s how scientific journals work nowadays.
Just thought you’d want to know.
If your results are too good, NEJM will reject your paper
How far the gatekeepers have fallen.
Many of the top people at NEJM who made outrageous statements in the NEJM are apparently trying to bury their mistakes- The traditional and the AI search engines are both making it hard to find their ivermectin misformation statements, etc. Must be filters on the AI and the NLM. Scary